Thursday, 26 February 201508:00 | Registration & Coffee | 09:00 | | 09:45 | Widening the analytical bottleneck: Generating new insight into embryonic stem cell culture kinetics by combining microfluidic approaches with novel analytical methods
Nicolas Szita, Professor, University College London, United Kingdom
| 10:10 | “Cell-in-a-Box® live cell encapsulation technology: clinical experience and applications for stem cells”
John Dangerfield, COO, Austrianova, Singapore
| 10:35 | Coffee Break and Networking in Exhibition Area | 11:20 | Live Cell Flourescent Imaging Probe Development for Stem Cell Research
Young-Tae Chang, Associate Professor, National University of Singapore, Singapore
| 11:45 | Stem Cell Providing Biomaterial for Translational Medicine
Charlotte A E Hauser, Team Leader/Principal Research Scientist, Nanyang Technological University, Singapore
| 12:10 | Primary and Stem Cell Biomanufactruing Approaches and Successes
William Whitford, Strategic Solutions Leader, GE Healthcare, United States of America
John Cadwell, president/CEO, FiberCell Systems, United States of America
| 12:35 | Lunch Break and Networking in Exhibition Area | 14:00 |  | Keynote Presentation Stem Cell based Therapy for Tissue Regeneration
Minoru Ueda, Professor, Nagoya University, Japan
|
| 14:45 | Secreted MSC therapeutic is an exosome
Sai Kiang Lim, Research Director, Institute of Medical Biology, A*STAR, Singapore
| 15:10 | iHuman Platform and Application Potential for Health
Cao Tong, Vice Dean, Director of Oral Science Disciplines, NUHS, NUS Faculty of Dentistry, Singapore
| 15:35 | Coffee Break and Networking in Exhibition Area | 16:20 | Induced pluripotent stem cells (IPSCs) for cardiac applications
Philip Wong En Hou, Director, R&D Unit (RDU), National Heart Centre, Singapore
| 16:45 | Funding clinical stem cell research
Steven Myint, Senior fellow, Consultant, Adjunct Professor , A*star, ETPL, Duke-NUS, Singapore
| 17:10 | Present state of Stem Cell and Gene therapy and expectations of clinical application
Roy Calne, Visiting Professor, National University of Singapore (NUS), Surgery, Singapore
| 17:35 | PANEL DISCUSSION- "Stem cells versus gene therapy as potential therapy in human disease" | 18:20 | End of Day One | 18:30 | Bus leaves from Academia to Hotel Fort Canning | 19:00 | Reception Evening at Hotel Fort Canning |
Friday, 27 February 201508:00 | Registration & Coffee | 09:00 | | 09:45 | Adipose Stem Cells: Potential for Metabolic Reprogramming
Shigeki Sugii, Group Leader/Assistant Professor, Singapore Bioimaging Consortium/Duke NUS Graduate Medical School, Singapore
| 10:10 | Opportunities and challenges for commercial banking of adipose stem cells
Teck Sin Lim, Founder, Adigenics, Singapore
Pamela Mok, Project Manager, Adigenics, Singapore
| 10:35 | Coffee Break and Networking in Exhibition Area | 11:20 | .jpg) | Keynote Presentation Discovery of Muse Cells shifts the Paradigm of Mesenchymal Stem Cells
Mari Dezawa, Professor and Chair, Department of Stem Cell Biology and Histology & Department of Anatomy and Anthropology, Tohoku University, Japan
We discovered non-tumorigenic pluripotent stem cells, Multilineage differentiating Stress Enduring (Muse) cells, that reside in the bone marrow and adipose tissue, and are collectable as SSEA-3(+) cells. They correspond to several percent of mesenchymal stem cells collected from these tissues. They are stress-tolerant, express pluripotency markers despite low telomerase activity, and are able to self-renew and generate cells of all three germ layers from a single cell. A highly useful feature of Muse cells is their specific ability to detect damage signals, which allows them to migrate toward and home into damaged tissues when infused into the peripheral blood stream where they can spontaneously differentiate into cells compatible with the homed-into tissue. These activities were confirmed in models of fulminant hepatitis, muscle degeneration, and skin injury. These effects are not recognized in remainder of mesenchymal cells, namely non-Muse cells.
Thus, they are feasible for safe and efficient cell based-therapy.
|
| 12:05 | Making Clinical Quality Cells From hES Cells Using Laminin-Based Cell Culture Substrata
Karl Tryggvason, Professor, Duke-NUS Graduate Medical School & Karolinska Institutet, Stockholm, Singapore
| 12:30 | Lunch Break and Networking in Exhibition Area | 14:00 | Up-regulation of MafA renders embryonic progenitor-derived insulin-producing cells towards maturation and functional improvement both in vitro and in vivo
GuoDong Li, Snr Principal Research Scientist , Singapore General Hospital (SGH), Singapore
| 14:25 | Characterization of microRNA-17-92 cluster in human gallbladder cancer stem cells
Fanyin Meng, Assistant Professor, Baylor-Scott & White Healthcare, United States of America
| 14:50 | Engineering functional durable engineered blood vessels from human induced pluripotent stem cells
Rekha Samuel, Professor, Christian Medical College, India
| 15:15 | Tri-lineage cardiac cell therapy of hiPSCs: a pre-clinical study
Ye Lei, Principal Investigator, National Heart Research Institute Singapore/ National Heart Centre Singapore, Singapore
| 15:40 | Coffee Break and Networking in Exhibition Area | 16:25 | Regulating clinical uses of autologous adult stem cells: an international review
Tamra Lysaght, Assistant Professor , National University of Singapore, Singapore
| 16:50 | Reducing Cell Manufacturing CoGs While Improving Product Quality - Can One Platform Do It All?
Kim Raineri, Business Director, Lonza Bioscience Singapore, Singapore
| 17:15 | Preclinical Stem Cells Studies: Safety and Regulatory Considerations related to Human-derived Cell-based Therapeutics
Itschak Lamensdorf, CEO, Pharmaseed Ltd., Israel
| 17:40 | PANEL DISCUSSION - Regulatory Affairs | 18:25 | Close of Conference |
|
Add to Calendar ▼2015-02-26 00:00:002015-02-27 00:00:00Europe/LondonClinical Applications of Stem CellsClinical Applications of Stem Cells in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
.png)
